Wikum Dinalankara

Dr. Wikum Dinalankara


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
CZClaudio Zanettini
Claudio Zanettini
MOMohamed Omar
Mohamed Omar
WDWikum Dinalankara
Wikum Dinalankara
EIEddie Luidy Imada
Eddie Luidy Imada
ECElizabeth Colantuoni
Elizabeth Colantuoni
LMLuigi Marchionni
Luigi Marchionni
The COVID-19 mortality rate is higher in the elderly and in those with pre-existing chronic medical conditions. The elderly also suffer from increased morbidity and mortality from seasonal influenza infections; thus, an annual influenza vaccination is recommended for them. In this study, we explore a possible county-level association between influenza vaccination coverage in people aged 65 years and older and the number of deaths from COVID-19. To this end, we used COVID-19 data up to 14 December 2020 and US population health data at the county level. We fit quasi-Poisson regression models using influenza vaccination coverage in the elderly population as the independent variable and the COVID-19 mortality rate as the outcome variable. We adjusted for an array of potential confounders using different propensity score regression methods. Results show that, on the county level, influenza vaccination coverage in the elderly population is negatively associated with mortality from COVID-19, using different methodologies for confounding adjustment. These findings point to the need for studying the relationship between influenza vaccination and COVID-19 mortality at the individual level to investigate any underlying biological mechanisms.

20 February 2020 in Genome Research
Verified
Journal Article
Open access
PDF file
EIEddie Luidy Imada
Eddie Luidy Imada
DSDiego Fernando Sanchez
Diego Fernando Sanchez
LCLeonardo Collado-Torres
Leonardo Collado-Torres
CWChristopher Wilks
Christopher Wilks
TMTejasvi Matam
Tejasvi Matam
LMLuigi Marchionni
Luigi Marchionni
Long noncoding RNAs (lncRNAs) have emerged as key coordinators of biological and cellular processes. Characterizing lncRNA expression across cells and tissues is key to understanding their role in determining phenotypes, including human diseases. We present here FC-R2, a comprehensive expression atlas across a broadly defined human transcriptome, inclusive of over 109,000 coding and noncoding genes, as described in the FANTOM CAGE-Associated Transcriptome (FANTOM-CAT) study. This atlas greatly extends the gene annotation used in the originalrecount2resource. We demonstrate the utility of the FC-R2 atlas by reproducing key findings from published large studies and by generating new results across normal and diseased human samples. In particular, we (a) identify tissue-specific transcription profiles for distinct classes of coding and noncoding genes, (b) perform differential expression analysis across thirteen cancer types, identifying novel noncoding genes potentially involved in tumor pathogenesis and progression, and (c) confirm the prognostic value for several enhancer lncRNAs expression in cancer. Our resource is instrumental for the systematic molecular characterization of lncRNA by the FANTOM6 Consortium. In conclusion, comprised of over 70,000 samples, the FC-R2 atlas will empower other researchers to investigate functions and biological roles of both known coding genes and novel lncRNAs.

16 April 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
WDWikum Dinalankara
Wikum Dinalankara
QKQian Ke
Qian Ke
YXYiran Xu
Yiran Xu
LJLanlan Ji
Lanlan Ji
NPNicole Pagane
Nicole Pagane
DGDonald Geman
Donald Geman
Significance: Technological advances enable increasingly comprehensive profiling of the molecular landscapes of cells, and these data can inform the personalized treatment of complex diseases. Two major obstacles are the complexity of these data and the high degree of person-to-person heterogeneity. We develop a highly simplified, personalized data representation by comparing the profile of an individual to the range of landscapes in a baseline population, thereby mimicking basic clinical diagnostic testing for departures of selected variables from normal levels. Moreover, our method can be applied to any data modality and at any level of granularity, from single features to any subset of features treated as a single entity, for example the gene expression levels in a pathway. Experiments involve both healthy human tissues and various cancer subtypes.

17 February 2026 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
WDWikum Dinalankara
Wikum Dinalankara
CSChandler Sy
Chandler Sy
JCJiani Chai
Jiani Chai
PBPaul B. Barone
Paul B. Barone
LMLuigi Marchionni
Luigi Marchionni
PSPaul D. Simonson
Paul D. Simonson
Minimal/measurable residual disease detection is routinely performed as part of post‐diagnostic treatment plans for many types of cancer, for which multiparameter flow cytometry is one possible modality frequently used. We propose a machine learning approach for binary prediction of minimal residual disease status with flow cytometry data. Our method involves the projection of cells from the original feature space to a low‐dimensional embedding in which cells are clustered by similarity, and the cluster‐wise cell proportions are used for prediction as well as regression. This is a weakly supervised approach in that the only annotation required for the training set data is the percentage of neoplastic cells present in each case. We demonstrate the applicability of our method with respect to a cohort of chronic lymphocytic leukemia patient data to obtain high levels of accuracy. We contrast our approach with other proposed machine learning methods for application to minimal residual disease prediction.

25 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
QKQian Ke
Qian Ke
WDWikum Dinalankara
Wikum Dinalankara
LYLaurent Younes
Laurent Younes
DGDonald Geman
Donald Geman
LMLuigi Marchionni
Luigi Marchionni
Cancer cells display massive dysregulation of key regulatory pathways due to now well-catalogued mutations and other DNA-related aberrations. Moreover, enormous heterogeneity has been commonly observed in the identity, frequency and location of these aberrations across individuals with the same cancer type or subtype, and this variation naturally propagates to the transcriptome, resulting in myriad types of dysregulated gene expression programs. Many have argued that a more integrative and quantitative analysis of heterogeneity of DNA and RNA molecular profiles may be necessary for designing more systematic explorations of alternative therapies and improving predictive accuracy. We introduce a representation of multi- omics profiles which is sufficiently rich to account for observed heterogeneity and support the construction of quantitative, integrated, metrics of variation. Starting from the network of interactions existing in Reactome, we build a library of “paired DNA-RNA aberrations” that represent prototypical and recurrent patterns of dysregulation in cancer; each two-gene “Source-Target Pair” (STP) consists of a “source” regulatory gene and a “target” gene whose expression is plausibly “controlled” by the source gene. The STP is then “aberrant” in a joint DNA-RNA profile if the source gene is DNA-aberrant ( e.g. , mutated, deleted, or duplicated), and the downstream target gene is “RNA-aberrant”, meaning its expression level is outside the normal, baseline range. With M STPs, each sample profile has exactly one of the 2 M possible configurations. We concentrate on subsets of STPs, and the corresponding reduced configurations, by selecting tissue-dependent minimal coverings, defined as the smallest family of STPs with the property that every sample in the considered population displays at least one aberrant STP within that family. These minimal coverings can be computed with integer programming. Given such a covering, a natural measure of cross-sample diversity is the extent to which the particular aberrant STPs composing a covering vary from sample to sample; this variability is captured by the entropy of the distribution over configurations. We apply this program to data from TCGA for six distinct tumor types (breast, prostate, lung, colon, liver, and kidney cancer). This enables an efficient simplification of the complex landscape observed in cancer populations, resulting in the identification of novel signatures of molecular alterations which are not detected with frequency-based criteria. Estimates of cancer heterogeneity across tumor phenotypes reveals a stable pattern: entropy increases with disease severity. This framework is then well-suited to accommodate the expanding complexity of cancer genomes and epigenomes emerging from large consortia projects. Author Summary: A large variety of genomic and transcriptomic aberrations are observed in cancer cells, and their identity, location, and frequency can be highly indicative of the particular subtype or molecular phenotype, and thereby inform treatment options. However, elucidating this association between sets of aberrations and subtypes of cancer is severely impeded by considerable diversity in the set of aberrations across samples from the same population. Most attempts at analyzing tumor heterogeneity have dealt with either the genome or transcriptome in isolation. Here we present a novel, multi-omics approach for quantifying heterogeneity by determining a small set of paired DNA-RNA aberrations that incorporates potential downstream effects on gene expression. We apply integer programming to identify a small set of paired aberrations such that at least one among them is present in every sample of a given cancer population. The resulting “coverings” are analyzed for six cancer cohorts from the Cancer Genome Atlas, and facilitate introducing an information-theoretic measure of heterogeneity. Our results identify many known facets of tumorigenesis as well as suggest potential novel genes and interactions of interest. Data Availability Statement: RNA-Seq data, somatic mutation data and copy number data for The Cancer Genome Atlas were obtained through the Xena Cancer Genome Browser database ( https://xenabrowser.net ) from individual cancer type cohorts. Computational functionality for the optimization procedure is provided at https://github.com/wikum/lpcover and the code for the analysis in the manuscript is provided at https://github.com/wikum/CoveringAnalysis . Processed data in the form of TAB delimited files, and selected tissue-level coverings (in excel format) are provided as additional supplementary material and are also available from the Marchionni laboratory website ( http://marchionnilab.org/signatures.html )

5 April 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WDWikum Dinalankara
Wikum Dinalankara
QKQian Ke
Qian Ke
DGDonald Geman
Donald Geman
LMLuigi Marchionni
Luigi Marchionni
Given the ever-increasing amount of high-dimensional and complex omics data becoming available, it is increasingly important to discover simple but effective methods of analysis. Divergence analysis transforms each entry of a high-dimensional omics profile into a digitized (binary or ternary) code based on the deviation of the entry from a given baseline population. This is a novel framework that is significantly different from existing omics data analysis methods: it allows digitization of continuous omics data at the univariate or multivariate level, facilitates sample level analysis, and is applicable on many different omics platforms. The divergence package, available on the R platform through the Bioconductor repository collection, provides easy-to-use functions for carrying out this transformation. Here we demonstrate how to use the package with data from the Cancer Genome Atlas.